New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
December 19, 2012
13:24 EDTABC, MCK, GSK, CAHGlaxoSmithKline settles nasal spray litigation for $150M, Reuters reports
GlaxoSmithKline Plc (GSK) has reached a preliminary $150M settlement with U.S. drug wholesalers regarding generic nasal spray litigation, according to Reuters. Reference Link
News For GSK;ABC;CAH;MCK From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
May 29, 2015
15:45 EDTCAHCardinal Health to hold a meeting
Cardinal Health Dublin Day to be held at the company's headquarters in Dublin, OH on June 5 at 10 am.
15:11 EDTABCAmerisourceBergen reverses after report of potential Humana sale
Subscribe for More Information
09:49 EDTMCKMcKesson completes acquisition of Drogheria & Alimentari for approx. $79M
McCormick & Company announced that it has completed the purchase of 100% of the shares of Drogheria & Alimentari, a privately held company based in Italy. McCormick announced the agreement to acquire D&A on February 20. Subject to certain closing adjustments, McCormick expects to record a purchase price for D&A of EUR72M, or approximately $79M. This expected purchase price consists of a EUR50M cash payment that was funded with cash and debt, and a potential earn-out payment of up to EUR35M that has a preliminary acquisition-date fair value of EUR22M. The potential earn-out payment is payable to D&A's former owners in 2018 upon the achievement of specified financial performance by D&A. Once the preliminary acquisition-date fair value of the potential earn-out payment is finalized, changes in the fair value will be recognized in income on an on-going basis until settlement in 2018. Due to the estimated impact of transaction and integration costs, McCormick expects no earnings per share impact in 2015. In 2016, McCormick expects the acquisition to be fully accretive, excluding any net increase in fair value of the potential earn-out payment.
09:42 EDTMCKMcKesson management to meet with UBS
Subscribe for More Information
09:16 EDTCAH, ABC, MCKBofA/Merrill healthcare tech analyst holds analyst/industry conference call
Analyst Willoughby discusses relevant themes across the Healthcare Distribution & Technology subsectors on an Analyst/Industry conference call to be held on June 1 at 11 am.
May 28, 2015
10:16 EDTMCKMcKesson management to meet with Deutsche Bank
Subscribe for More Information
08:04 EDTCAHCardinal Health confirms binding offer to acquire Cordis accepted from JNJ
Subscribe for More Information
08:02 EDTCAHJohnson & Johnson accepts binding offer from Cardinal Health to acquire Cordis
Subscribe for More Information
May 27, 2015
10:58 EDTMCKMcKesson management to meet with UBS
Subscribe for More Information
May 26, 2015
08:14 EDTGSKBoston Biotech Conferences to hold a conference
Subscribe for More Information
May 22, 2015
10:52 EDTGSKJPMorgan says Actavis shares cheap compared to peers
Subscribe for More Information
May 21, 2015
08:09 EDTABCAmerisourceBergen has a conference call hosted by JPMorgan
JPMorgan Analyst Gill will host a conference call with CEO Steve Collis on May 28 at 11 am.
07:37 EDTGSKPfizer replaces AbbVie as top global pharma pick at Jefferies
Subscribe for More Information
May 20, 2015
07:46 EDTGSKDeutsche Bank positive on potential Pfizer, GSK merger
Deutsche Bank analyst Gregg Gilbert believes a large foreign deal for Pfizer (PFE) may make sense and says a buyout of GlaxoSmithKline (GSK) could be "materially" accretive to earnings while improving the company's tax situation over time. Gilbert assumes a $60 per share buyout price for GlaxoSmithKline in a research note this morning titled "Introducing 'PfizerKline'". The stock closed yesterday up 2c to $44.68. Gilbert reiterates a Buy rating on Pfizer with a $41 price target. Shares ended yesterday up 23c to $34.21.
May 19, 2015
09:25 EDTGSKGlaxoSmithKline asthma drug overused, risks underappreciated, ProPublica says
Subscribe for More Information
06:55 EDTGSKGenocea could be takeover target after data, says Piper Jaffray
Piper Jaffray analyst Edward Tenthoff expects Genocea Biosciences (GNCA) will report positive Phase II GEN-003 post-immunization results late in Q2. GEN-003 is a therapeutic vaccine for genital herpes targeting Herpes Simplex Virus Type 2. Positive GEN-003 data could position Genocea as a potential acquisition target by a larger vaccine player, Tenthoff tells investors today in a research note. Large vaccine makers include Sanofi (SNY), Merck (MRK), GlaxoSmithKline (GSK), Pfizer (PFE) and Novartis (NVS). The analyst reiterates an Overweight rating on Genocea with a $14 price target. Shares of the clinical-stage vaccine developer with a $227M market capitalization closed yesterday up 83c to $10.22.
May 18, 2015
10:01 EDTABCOn The Fly: Analyst Downgrade Summary
Subscribe for More Information
07:42 EDTABCAmerisourceBergen downgraded to Market Perform from Outperform at Cowen
Subscribe for More Information
07:22 EDTABCUBS to hold a conference
Global Healthcare Conference is being held in New York on May 18-20 with webcasted company presentations to begin on May 18 at 8 am; not all company presentations may be webcasted. Webcast Link

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use